Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer-Reference-Cited by-同舟云学术

Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer

Published:2020-01-17 Issue:3 Volume:6 Page:
ISSN:2375-2548
Container-title:Science Advances
language:en
Short-container-title:Sci. Adv.

Author:

Huang Kuan-Wei¹^ORCID,Hsu Fu-Fei²^ORCID,Qiu Jiantai Timothy³⁴⁵^ORCID,Chern Guann-Jen¹,Lee Yi-An¹,Chang Chih-Chun¹,Huang Yu-Ting⁶^ORCID,Sung Yun-Chieh¹,Chiang Cheng-Chin¹,Huang Rui-Lin¹,Lin Chu-Chi⁵^ORCID,Dinh Trinh Kieu¹,Huang Hsi-Chien¹,Shih Yu-Chuan¹,Alson Donia⁵^ORCID,Lin Chun-Yen³⁷^ORCID,Lin Yung-Chang⁸^ORCID,Chang Po-Chiao⁷,Lin Shu-Yi⁶^ORCID,Chen Yunching¹^ORCID

Affiliation:

1. Institute of Biomedical Engineering and Frontier Research Center on Fundamental and Applied Sciences of Matters, National Tsing Hua University, Hsinchu 30013, Taiwan.

2. Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.

3. College of Medicine, Chang Gung University, Taoyuan, Taiwan.

4. Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

5. Department of Biomedical Sciences, School of Medicine, Chang Gung University, Taoyuan, Taiwan.

6. Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli County 35053, Taiwan.

7. Division of Hepatology, Department of Gastroenterology and Hepatology, Linkou Medical Center; Chang Gung Memorial Hospital, Taoyuan, Taiwan.

8. Division of Medical Oncology/Hematology, Chang Gung Memorial Hospital, Taoyuan, Taiwan.

Abstract

The dual-targeted immunogene therapy that inhibits PD-L1 and provides IL-2 can enhance the therapeutic efficacy of cancer vaccine.

Funder

Ministry of Science and Technology

Ministry of Education

Chang Gung Memorial Hospital

National Health Research Institutes

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference40 articles.

1. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations

2. IL-2: The First Effective Immunotherapy for Human Cancer

3. The efficacy of a novel vaccine approach using tumor cells that ectopically express a codon-optimized murine GM-CSF in a murine tumor model

4. The hallmarks of successful anticancer immunotherapy

5. Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy

Cited by 192 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging tin-based engineering for tumor treatment: Current advances and forward opportunities;Coordination Chemistry Reviews;2024-12

2. PicoGreen assay for nucleic acid quantification - Applications, challenges, and solutions;Analytical Biochemistry;2024-09

3. Dual and multi-immune activation strategies for emerging cancer immunotherapy;Materials Today;2024-09

4. Bioinformatics analysis of BTK expression in lung adenocarcinoma: implications for immune infiltration, prognostic biomarkers, and therapeutic targeting;3 Biotech;2024-08-28

5. Advances in Immunomodulatory Mesoporous Silica Nanoparticles for Inflammatory and Cancer Therapies;Biomolecules;2024-08-25